Abstract |
Serotonin-1F receptor (5-HT1F) agonists may relieve acute migraine without vasoconstriction. We conducted a review of preclinical and clinical data that assessed the potential link between migraine and 5-HT1F activation. (i) A high correlation exists between the potency of various 5-HT1 receptor agonists in the guinea pig dural plasma protein extravasation assay and their 5-HT1F receptor binding affinity. (ii) 5-HT1F receptors are on the trigeminal system, and may participate in blocking migraine pain transmission through the trigeminal ganglion and nucleus caudalis. (iii) 5-HT1F receptors are located on glutamate-containing neurones and their activation might inhibit glutamate release; glutamate excess may play a role in migraine. (iv) Selective 5-HT1F receptor agonists ( LY334370; LY344864) are effective in preclinical migraine models and are non-vasoconstrictive. (v) LY334370 is effective in acute migraine, and does not cause any symptoms/signs of coronary vasoconstriction. Preclinical experiments and clinical observations argue for a role of selective 5-HT1F agonists in migraine.
|
Authors | N M Ramadan, V Skljarevski, L A Phebus, K W Johnson |
Journal | Cephalalgia : an international journal of headache
(Cephalalgia)
Vol. 23
Issue 8
Pg. 776-85
(Oct 2003)
ISSN: 0333-1024 [Print] England |
PMID | 14510923
(Publication Type: Journal Article, Review)
|
Chemical References |
- Receptors, Serotonin
- Serotonin Receptor Agonists
- serotonin 1F receptor
|
Topics |
- Acute Disease
- Animals
- Clinical Trials as Topic
(statistics & numerical data)
- Humans
- Migraine Disorders
(drug therapy, metabolism)
- Receptors, Serotonin
(metabolism)
- Serotonin Receptor Agonists
(therapeutic use)
|